Introduction
============

Age-related macular degeneration (AMD) is a leading cause of blindness in Western countries, and its prevalence is increasing in Japan \[[@r1],[@r2]\]. AMD is thought to be a heterogeneous multifactorial disease associated with several environmental factors and genetic variants. Factors such as hypertension \[[@r3]\] and cigarette smoking \[[@r4]\] are closely related to the development of AMD. Identification of AMD-susceptibility genes might increase our ability to predict the risk of developing AMD. Complement factor H (*CFH*) is reportedly related to AMD in Caucasians \[[@r5]\]. In addition, age-related maculopathy susceptibility 2 (*ARMS2*) and high-temperature requirement factor A1 have been shown to be associated with AMD in both Japanese and Caucasian patients \[[@r6]-[@r10]\]. The *CFH* polymorphism Y402H has been reported to be associated with AMD in studies conducted worldwide. However, several Japanese studies have found Y402H to be unrelated to AMD \[[@r11]-[@r14]\]. Other studies of the Japanese population have shown an association between *CFH* [rs800292](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=800292) and AMD \[[@r14]-[@r16]\]. Two studies examined gene polymorphisms associated with retinal angiomatous proliferation (RAP) \[[@r17],[@r18]\].

In Japan, exudative AMD includes both neovascular AMD (nAMD) and serous retinal pigment epithelial detachment without choroidal neovascularization, while polypoidal choroidal vasculopathy (PCV) and RAP have been defined as specific forms of exudative AMD \[[@r19]\]. Reported frequencies of each subtype in the Japanese population are 35.3% for nAMD, 54.7% for PCV, and 4.5% for RAP \[[@r20]\]. PCV occurs in less than 8% of Caucasians \[[@r21]-[@r24]\]. Histopathological examination of PCV demonstrated choroidal vessels to be similar to those in atherosclerosis or choroidal neovascularization \[[@r25]\]. As these AMD subtypes may have different pathophysiological and genetic backgrounds, we undertook this study of the associations between genetic markers or mutations and individual AMD subtypes.

Several candidate genes for atherosclerosis have been reported. Elastin (*ELN*) is among the markers of atherosclerosis \[[@r26]\] and neovascularization \[[@r27],[@r28]\]. Kondo et al. \[[@r29]\] reported an *ELN* gene polymorphism [(rs2301995](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2301995)) to confer susceptibility only for PCV, not for nAMD. They reported the frequency of the [rs2301995](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2301995) polymorphism in the *ELN* gene to differ significantly between the PCV and control groups.

Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the homocysteine cycle. Hyperhomocysteinemia reportedly is a risk for AMD \[[@r30],[@r31]\] and induces vascular endothelial growth factor in the retina of a rat model \[[@r32]\]. Thus, the *MTHFR* gene is among the candidates for atherosclerosis susceptibility genes \[[@r33],[@r34]\].

The present study aimed to use single-nucleotide polymorphisms (SNPs) to investigate the relationships between AMD subtypes and potential susceptibility genes, *ARMS2*, *CFH*, *MTHFR*, and *ELN*, in Japanese subjects. We determined the frequencies of three AMD subtypes, along with the age and gender distributions of the study's participants. We also analyzed four SNPs for AMD subtype associations and calculated corresponding odds ratios (ORs).

Methods
=======

Subjects
--------

All AMD patients and control subjects were recruited at Nihon University Surugadai Hospital in Tokyo between 2001 and 2010. In total, 685 patients (478 men and 207 women; mean age 72.0±8.8 years) were diagnosed with AMD by color fundus photography, fluorescein angiography, and indocyanine green angiography. The patient group included 253 diagnosed with nAMD, 381 with PCV, and 51 with RAP. All study subjects were asked if they had a history of hypertension, diabetes mellitus, and/or smoking (including both previous and current smoking at the time of the study). In total, 277 subjects without AMD (111 men and 166 women; mean age 72.9±8.7 years) served as control subjects. There were no remarkable findings from the fundus examinations of the controls. Smokers were defined as current or former smokers, nonsmokers as subjects with no previous or current smoking history. Informed consent was obtained from all participants as per the protocol approved by the Human Studies Committee of Nihon University.

Genotyping
----------

DNA was extracted from peripheral blood leukocytes by the phenol and chloroform extraction technique \[[@r35],[@r36]\]. Briefly, the samples were centrifuged for 10 min at 1,500× g, and the pellet was resuspended in 3 ml of solution 1, which consisted of 10 mM tris (pH 7.5), 10 mM KCl, 10 mM MgCl~2~, and Nonidet P40 (Sigma, St. Louis, MO), and incubated on a rotator for 30 min. The tube was centrifuged as described above for 10 min, and the supernatant was removed to another tube. Two milliliters of solution 2 (10 mM Tris (pH 7.5), 10 mM KCl, 10 mM MgCl~2~, 50 mM NaCl, 5 mM EDTA (pH 8.0), 25 ml 10% SDS) and 10.4 ml of proteinase K (20 mg/ml H~2~O; Sigma) were added to the supernatant. After incubation on a rotator at 37 °C overnight, 2.2 ml of phenol was added and incubate on a rotator for 30 min. The sample was centrifuged as described above for 10 min, and the supernatant was removed with a large-bore tip to another tube. Phenol purification was repeated twice: 2.2 ml of phenol/ chloroform/isoamyl alcohol was added, and incubation and centrifugation were performed described; 2.2 ml of chloroform was added and incubation and centrifugation were performed again. The 400 ml of aqueous layer was transferred carefully to a new 1.5-ml microcentrifuge tube to which 1 ml of cold 100% ethanol was added, mixed, and incubated for 15 min at 20 °C. Genotyping was performed using the TaqMan SNP Genotyping Assay (Applied Biosystems, Carlsbad, CA). TaqMan SNP Genotyping Assays were performed using the method for Taq amplification \[[@r37],[@r38]\].

Plates were read on an SDS 7700 instrument with the end-point analysis mode of the SDS, version 1.6.3, software package (Applied Biosystems). Genotypes were determined visually, based on the dye-component fluorescent emission data depicted in the X-Y scatter plot of the SDS software. Genotypes were also automatically determined by applying signal processing algorithms of the software \[[@r35],[@r36]\].

Statistical analysis
--------------------

Data are shown as means, plus or minus standard deviation (±SD). Differences among the nAMD, PCV, RAP, and control groups were assessed by the ANOVA (ANOVA), followed by Fisher's protected least significant difference (PLSD) test. Hardy--Weinberg equilibrium was assessed by chi-square analysis. The overall distribution of the SNP alleles was determined using 2×2 contingency tables. The distributions of SNP genotypes in the AMD patients and the controls were tested using a 2-sided Fisher's exact test and multiple logistic regression analysis. Statistical significance was established at p\<0.05. Because we examined four SNPs, we applied multiple comparisons with a strict p value (0.05/SNP number in this study: four, p\<0.0125).

Logistic regression analyses for assessing the contributions of major risk factors and the independence of each SNP in relation to AMD were performed using SPSS software for Windows, version 12 (SPSS, Chicago, IL).

Results
=======

The clinical features of AMD patients and the control group are shown in [Table 1](#t1){ref-type="table"}. There were no significant differences in age or history of hypertension between the AMD patients and the control group. There were significantly more males, and the frequencies of smoking were higher in the patient group than in the control group. However, there were significantly fewer subjects with diabetes mellitus in the patient group than in the control group.

###### Characteristics of study participants.

  **Parameters**          **Total AMD**                **Case**   **Control**              
  ----------------------- --------------- ------------ ---------- ------------- ---------- ----------
  No. of subjects         685                          253        381           51         277
  Age (mean±SD)           72.0±8.8        0.146        73.7±7.5   69.9±9.1      80.1±6.8   72.9±8.7
  Male/female             478/207         \<0.0001\*   188/65     271/110       19/32      111/166
  Hypertension (%)        39.1            0.254        38.3       39.4          41.2       43.0
  Diabetes mellitus (%)   10.7            \<0.0001\*   12.6       9.4           9.8        19.5
  Smoking (%)             34.7            \<0.0001\*   34.8       37.3          15.7       17.7

Abbreviations: AMD represents age-related macular degeneration, nAMD represents neovascular age related macular degeneration, PCV represents polypoidal choroidal vasculopathy, RAP represents retinal angiomatous proliferation, N represents number, SD represents standard deviation. Information on hypertension, diabetes mellitus and smoking was obtained from the medical history of each patient. p-values reflect comparisons between case and control groups. p-values were calculated using Fisher\'s exact test. \*p\<0.05

Genotype and allele distributions of the four SNPs are shown in [Table 2](#t2){ref-type="table"}. All four SNPs in the controls were in Hardy--Weinberg equilibrium (data not shown, p\>0.05). The genotype-dominant or recessive distribution of all four SNPs differed significantly between the control and AMD groups. Subtype analysis revealed a significant difference between the controls and the AMD patients in genotype distributions for all AMD subtypes, and both [rs800292](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=800292) (*CFH*) and [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924) (*ARMS2*). There were significant differences in the genotype distributions of [rs2301995](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2301995) (*ELN*) and [rs1801133](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1801133) (*MTHFR*) between the controls and nAMD patients.

###### Genotype and allele distributions in AMD patients and control group

  **Susceptibility genotype**                                                                            **Total AMD patients**   **nAMD**   **PCV**       **RAP**   **Control**                                                                              
  ------------------------------------------------------------------------------------------------------ ------------------------ ---------- ------------- --------- ------------- ------------- ----- ------- ------------- ---- ------- ------------- ----- ------
  [rs800292](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=800292)**(*CFH*) Genotype**                                                                                                                                                              
  G/G                                                                                                    386                      56.4       p\<0.0001\*   147       58.1          p\<0.0001\*   210   55.1    p\<0.0001\*   29   56.9    0.011\*       100   36.1
  G/A                                                                                                    263                      38.4                     93        36.8                        150   39.4                  20   39.2                  141   50.9
  A/A                                                                                                    36                       5.3                      13        5.1                         21    5.5                   2    3.9                   36    1.3
  **G/G**                                                                                                386                      56.4       p\<0.0001\*   147       58.1          p\<0.0001\*   210   55.1    p\<0.0001\*   29   56.9    0.005\*       100   36.1
  **GA/AA**                                                                                              299                      43.6                     106       41.9                        171   44.9                  22   43.1                  177   63.9
  ***AA***                                                                                               36                       5.3        p\<0.0001\*   13        5.1           0.002\*       21    5.5     0.0008\*      2    3.9     0.063         36    1.3
  ***GA/GG***                                                                                            649                      94.7                     240       94.9                        360   94.5                  49   96.1                  241   8.7
  [rs800292](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=800292)**(*CFH*) Allele**                                                                                                                                                                
  G                                                                                                      1035                     75.5       p\<0.0001\*   387       76.5          p\<0.0001\*   570   74.8    p\<0.0001\*   78   76.5    0.004\*       341   61.6
  A                                                                                                      335                      24.5                     119       23.5                        192   25.2                  24   23.5                  213   38.4
  [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924)**(*ARMS2*) Genotype**                                                                                                                                                        
  G/G                                                                                                    142                      20.7       p\<0.0001\*   46        18.2          p\<0.0001\*   94    24.7    p\<0.0001\*   2    3.9     p\<0.0001\*   99    35.7
  G/T                                                                                                    253                      36.9                     81        32.0                        162   42.5                  10   19.6                  142   51.3
  T/T                                                                                                    290                      42.3                     126       49.8                        125   32.8                  39   76.5                  36    1.3
  **GG**                                                                                                 142                      20.7       p\<0.0001\*   46        18.2          p\<0.0001\*   94    24.7    0.002\*       2    3.9     p\<0.0001\*   99    35.7
  **GT+TT**                                                                                              543                      79.3                     207       81.8                        287   0.753                 49   0.961                 178   64.3
  ***TT***                                                                                               290                      42.3       p\<0.0001\*   126       49.8          p\<0.0001\*   125   32.8    p\<0.0001\*   39   76.5    p\<0.0001\*   36    13.0
  ***GT+GG***                                                                                            395                      57.7                     127       50.2                        256   67.2                  12   23.5                  241   87.0
  [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924)**(*ARMS2*) Allele**                                                                                                                                                          
  G                                                                                                      537                      39.2       p\<0.0001\*   173       34.2          p\<0.0001\*   350   45.9    p\<0.0001\*   14   13.7    p\<0.0001\*   340   61.4
  T                                                                                                      833                      60.8                     333       65.8                        412   54.1                  88   86.3                  214   38.6
  [rs2301995](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2301995)**(*ELN*) Genotype**                                                                                                                                                            
  C/C                                                                                                    457                      66.7       0.037\*       181       71.5          0.013\*       239   62.7    0.237         37   72.5    0.176         165   59.6
  C/T                                                                                                    207                      30.2                     64        25.3                        130   34.1                  13   25.5                  96    34.7
  T/T                                                                                                    21                       3.1                      8         3.2                         12    3.1                   1    2                     16    5.7
  **CC**                                                                                                 457                      66.7       0.035\*       181       71.5          0.004\*       239   62.7    0.41          37   72.5    0.08          165   59.6
  **CT+TT**                                                                                              228                      33.3                     72        28.5                        142   37.3                  14   27.5                  112   40.4
  ***TT***                                                                                               21                       3.1        0.047\*       8         3.2           0.148         12    3.1     0.099         1    2       0.259         16    5.8
  ***CT+CC***                                                                                            664                      96.9                     245       96.8                        369   96.9                  50   9.8                   261   94.2
  [rs2301995](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2301995)**(*ELN*) Allele**                                                                                                                                                              
  C                                                                                                      1121                     81.8       0.013\*       426       84.2          0.003\*       608   79.8    0.206         87   85.3    0.059         426   76.9
  T                                                                                                      249                      18.2                     80        15.8                        154   20.2                  15   14.7                  128   23.1
  [rs1801133](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1801133)**(*MTHFR*) Genotype**                                                                                                                                                          
  C/C                                                                                                    250                      36.5       0.089         110       43.5          0.002\*       123   32.3    0.692         17   33.3    0.819         81    29.2
  C/T                                                                                                    330                      48.2                     105       41.5                        198   52.0                  27   52.9                  152   54.9
  T/T                                                                                                    105                      15.3                     38        15.0                        60    15.7                  7    13.7                  44    15.9
  **CC**                                                                                                 250                      36.5       0.032\*       110       43.5          0.001\*       123   32.3    0.404         17   33.3    0.558         81    29.2
  **CT+TT**                                                                                              435                      63.5                     143       56.5                        258   67.7                  34   66.7                  196   70.8
  ***TT***                                                                                               105                      15.3       0.829         38        15.0          0.783         60    15.7    0.962         7    13.7    0.696         44    15.9
  ***CT+CC***                                                                                            580                      84.7                     215       85.0                        321   84.3                  44   86.3                  233   84.1
  [rs1801133](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1801133)**(*MTHFR*) Allele**                                                                                                                                                            
  C                                                                                                      830                      60.6       0.114         325       64.2          0.012\*       444   58.3    0.564         61   59.8    0.558         314   56.7
  T                                                                                                      540                      39.4                     181       35.8                        318   41.7                  41   40.2                  240   43.3

Abbreviations: AMD represents age-related macular degeneration nAMD represents neovascular age-related macular degeneration PCV represents polypoidal choroidal vasculopathy RAP represents retinal angiomatous proliferation. p-values for the comparison between cases and controls. p-values for genotypes were calculated by Fisher\'s exact test. \*p\<0.05. p-values for multiple comparison. Bold font indicate dominant model and bold italic font indicate recessive models.

The results of logistic regression analysis, adjusted for confounding factors, are shown in [Table 3](#t3){ref-type="table"}. This analysis was performed for the dominant or recessive genotype models that showed significant results, as presented in [Table 2](#t2){ref-type="table"}. Susceptibility genotypes were those with high frequencies in patient groups in case-control studies. *CFH* genotype distributions differed significantly between the controls and all AMD subtypes, especially for nAMD (p=7.66×10^−8^; OR: 2.90). Similarly, the *ARMS2* genotype distributions differed significantly between the controls and all AMD subtypes. In particular, the TT genotype of the *ARMS2* gene was significantly more frequent in RAP patients (p=1.54×10^−13^, OR: 22.18). In contrast, SNPs in the *ELN* (p=0.022) and *MTHFR* (p=2.50×10^−3^) genes were associated only with nAMD, that is, not with either PCV or RAP.

###### Logistic regression analysis with adjustment for confounding factors.

  **Susceptibility genotype**                                                                   **Total AMD patients**   **nAMD**   **PCV**      **RAP**                                                                                                  
  --------------------------------------------------------------------------------------------- ------------------------ ---------- ------------ -------------- ---------- ------------- ------------- ---------- ------------ -------------- ----------- -------------
  [rs800292](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=800292)**(*CFH*)**                                                                                                                                                                   
  GG (rec)                                                                                      2.36×10^−8^              **2.47**   1.79--3.41   7.66×10^−8^    **2.90**   1.96--4.27    1.42×10^−5^   **2.26**   1.55--3.27   0.029          **2.09**    1.08--4.06
  GG+GA (dom)                                                                                   3.33×10^−4^              **2.71**   1.57--4.67   6.22×10^−3^    **2.68**   1.32--5.34    8.46×10^−3^   **2.32**   1.23--4.39                               
  [rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924)**(*ARMS2*)**                                                                                                                                                             
  GT+TT (dom)                                                                                   3.85×10^−6^              **2.29**   1.61--3.26   2.00×10^−5^    **2.59**   1.67--4.02    5.88×10^−3^   **1.75**   1.17--2.62   0.001          **11.60**   2.69--50.03
  TT (rec)                                                                                      2.37×10^−19^             **5.74**   3.76--8.77   3.24×10^−16^   **7.03**   4.40--11.23   1.54×10^−6^   **3.37**   2.09--5.42   1.54×10^−13^   **22.18**   9.74--50.50
  [rs2301995](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2301995)**(*ELN*)**                                                                                                                                                                 
  CC (rec)                                                                                                                                       2.2×10^−2^     **1.58**   1.07--2.35                                                                      
  CC+CT (dom)                                                                                                                                                                                                                                              
  [rs1801133](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1801133)**(*MTHFR*)**                                                                                                                                                               
  CC (rec)                                                                                                                                       2.50×10^−3^    **1.82**   1.23--2.68                                                                      
  CC+CT (dom)                                                                                                                                                                                                                                              

Logistic regression analysis was performed for each genotype with adjustment for confounding factors (age, gender, hypertension, diabetes mellitus and smoking). Abbreviations: AMD represents age-related macular degeneration, nAMD represents neovascular age-related macular degeneration, PCV represents polypoidal choroidal vasculopathy, RAP represents retinal angiomatous proliferation, CI represents confidence intervals, dom represents dominant model, rec represents recessive model. p-values for comparisons between the case and control groups. p-values for genotypes were calculated using Fisher\'s exact test. p\<0.05. Blanks indicate no siginificant difference.

Multiple logistic regression analysis was performed to determine the independence of the four SNPs as risk factors for AMD ([Table 4](#t4){ref-type="table"}). Each p value and 95% CI for the SNPs showed a statistically significant difference after adjustment for all confounding factors. Each SNP was confirmed to be an independent risk factor for AMD.

###### Odds ratios and 95% confidence intervals for each model.

  **Susceptibility genotype**   **p-value**    **OR**     **95% CI**
  ----------------------------- -------------- ---------- ------------
  CFH recessive model           4.27×10^−7^    **2.17**   1.60--2.94
  ARMS2 recessive model         2.76×10^−15^   **4.73**   3.22--6.99
  ELN recessive model           0.018          **1.44**   1.06--1.96
  MTHFR recessive model         0.037          **1.4**    1.02--1.94

p-values reflect the comparison between each gene. Abbreviations: OR represents odds ratio CI represents confidence intervals.

Discussion
==========

Our results indicated significant differences between all AMD subtypes and the controls in the distributions of genotypes and alleles of SNPs in the *CFH* and *ARMS2* genes. Both the *CFH* SNP ([rs800292](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=800292)) and *ARMS2* SNP ([rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924)) are located within exons and are known to be I62V and A69S missense mutations. Although several studies have examined the functions of these genes, controversies concerning their exact functions persist \[[@r37],[@r38]\].

As in previous reports, the SNPs of *CFH* ([rs800292](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=800292)) and *ARMS2* ([rs10490924](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10490924)) were both strongly associated with AMD in our study. In comparing these two genes, the *ARMS2* SNP is a more powerful marker of AMD than is the *CFH* SNP. The odds ratio (OR) for *CFH* was equal in the three subtypes, suggesting that *CFH* might be a marker for all AMD subtypes. In contrast, the OR for *ARMS2* was markedly higher for RAP than for the other subtypes. These results may support the theory suggested by Hayashi et al. \[[@r18]\]. They reported an SNP in the *ARMS2* gene to be highly associated with all three subtypes, with the association being strongest for RAP and weakest for PCV. They concluded that PCV and RAP might thus be subtypes of AMD that are genetically distinct from nAMD. We agree with their conclusion. *ARMS2* gene might serve as strong genetic markers of RAP. There may be pathological distinctions among these three subtypes. The significant differences between these two SNPs in case-control studies using AMD subtypes might be explained as follows: 1) The *CFH* and *ARMS2* genes may influence a common factor such aging in all three subtypes. 2) An unknown gene might affect each of these genotypes.

We examined the histopathology of human PCV specimens excised during the diagnosis of nAMD. CD68-positive cells were detected around hyalinized vessels. Hypoxia-inducible factor (HIF)-1alpha positive inflammatory cells were located in the stroma of these specimens. Our results indicate that the hyalinization of choroidal vessels, like arteriosclerosis, is characteristic of PCV \[[@r27]\]. Other investigators reported that *ELN* is highly associated with the calcification of elastic fibers in human atherosclerotic plaques \[[@r26]\]. Therefore, the *ELN* gene was considered to be a candidate gene for PCV. Because the [rs2301995](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2301995) SNP in the *ELN* gene was already reported to be associated with PCV \[[@r30]\], we conducted association studies for all three subtypes using this SNP. Since [rs2301995](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2301995) is located in the intron, it is not clear whether this SNP affects gene function. Although a previous study demonstrated TT homozygosity to be a risk factor for PCV, we found CC homozygosity to be higher in the nAMD group. These findings suggest that the CC homozygosity of [rs2301995](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2301995) is related to nAMD rather than PCV.

In addition to these results, several other reports have demonstrated a relationship between the ELN protein and neovascularization \[[@r27],[@r28]\]. Skeie et al. \[[@r27]\] reported that *ELN* abnormalities might play a role in the neovascularization that occurs in AMD. Sivaprasad et al. \[[@r28]\] reported that serum ELN-derived peptides might increase the risk of conversion from early AMD to neovascular AMD. Taken together, these reports suggest that *ELN* might be related to neovascularization. To our knowledge, ours is the first report showing the *ELN* SNP ([rs2301995](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2301995)) to be associated with nAMD but to have no association with PCV. The previously reported, opposite results may be due to the different sample sizes in our study and that of Kondo et al. \[[@r29]\], who analyzed only 74 cases. We believe our results to be more reliable than theirs because our sample was much larger. Since we investigated only one SNP, we cannot conclude that the *ELN* gene has no association with PCV.

It is known that [rs1801133](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1801133) is a missense mutation in the *MTHFR* gene, which is located in the exon known as A222V. Although Haas et al. \[[@r39]\] concluded that this variant was not related to AMD, there is a widely accepted view that homocysteine is a risk factor for atherosclerosis \[[@r31],[@r33]\] and AMD \[[@r30]\]. Therefore, we examined the association between this variant and AMD subtypes in Japanese subjects. Significant differences were noted among the nAMD and control groups, suggesting *MTHFR* to be a potential marker of AMD. In addition, our results also indicate that nAMD might not be related to atherosclerosis. Most previous studies showed TT homozygosity to be more common in subjects with atherosclerosis than in those without it. However, we found the rate of CC homozygotes to be higher in the AMD group than in the controls. This is quite the opposite of previous reports on atherosclerosis. This variant may be a genetic marker that does not affect gene function, and the C or T allele may be linked to different susceptibility alleles for either atherosclerosis or AMD.

To our knowledge, this is the first application of logistic regression analysis to confounding factors known to be associated with AMD risk in three AMD subtypes ([Table 3](#t3){ref-type="table"}). All genotypes showing significant differences in the simple case-control study also yielded significant p values from the logistic regression analyses. These results suggest that each of the genotypes examined is an independent risk factor for AMD.

The present study is the first to examine potential correlations of the *MTHFR* and *ELN* genes with each of three AMD subtypes based on examinations of SNPs. Our findings suggest that polymorphisms of each gene are potentially useful genetic markers of AMD, and indicate that SNPs of the *ARMS2* gene may serve as strong genetic markers of RAP. The major limitation of this study is that only one SNP in each of the four genes was examined in a rather small numbers of patients. These results are preliminary, especially for RAP. Based on the present results, we plan further studies to investigate specific SNPs for each subtype of AMD, particularly those for PCV and RAP. Findings from these studies are anticipated to facilitate clarification of the causes of AMD.
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